SCHEMBL720334

SCHEMBL720334

Cc1c(C(Nc2ccc(C(=O)O)cc2)C2CCCCC2)oc2cccnc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RCE1 Q9Y256 8/20 0.59
TEAD4 Q15561 1/20 0.39
ALDH1A1 P00352 2/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
HIF1A Q16665 1/20 0.38
HSD17B10 Q99714 1/20 0.38
P4HB P07237 1/20 0.38
LCK P06239 1/20 0.36
JAK3 P52333 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
KDM4E B2RXH2 2/20 0.34
GAA P10253 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717537 0.90 RCE1 (0.48) RCE1TEAD4ALDH1A1CYP1A2CYP2C9
SCHEMBL3397932 0.87 GCG (0.48) RCE1
SCHEMBL3400480 0.86 RCE1 (0.45) RCE1TEAD4HPGD
SCHEMBL719620 0.84 RCE1 (0.54) RCE1TEAD4ALDH1A1TP53CYP1A2
SCHEMBL719113 0.83 RCE1 (0.46) RCE1TEAD4ALDH1A1CYP3A4CYP2C9
SCHEMBL719583 0.83 RCE1 (0.46) RCE1TEAD4ALDH1A1CYP3A4CYP2C9
SCHEMBL716868 0.82 MEN1 (0.47) RCE1CYP1A2HPGDKDM4E
SCHEMBL721580 0.81 RCE1 (0.40) RCE1TEAD4TP53HPGDKDM4E
SCHEMBL718024 0.81 GCG (0.43) RCE1TEAD4
SCHEMBL716915 0.80 RCE1 (0.45) RCE1TEAD4LCKJAK3CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RCE1 2661/4885TEAD4 253/4885ALDH1A1 504/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RCE1 2661/4885TEAD4 253/4885ALDH1A1 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.